IPM grows 4.1 per cent, valued at Rs 5939 crore in November 2012

The Indian pharmaceutical market (IPM) clocked a value of Rs 5,939 crore in November 2012, growing at 4.1 per cent. According to the monthly secondary sales data audit conducted by AIOCD-AWACS’ PharmaTrac, from a therapy perspective, sex stimulants/ rejuvenators clocked a 25 per cent growth.

The anti-diabetic market recorded the second highest growth at 15.6 per cent, resulting in Novo Nordisk, with its large insulin portfolio, showing the highest growth (32.5 per cent) among the top 50 corporates,

The cardiac segment followed with 8 per cent in chronic business. The anti-infective market had a growth of 3.3 per cent whereas respiratory market was little better at 3.9 pre cent growth.

The gastro and vitamins/minerals/ nutrients segments showed negligible growth whereas pain and analgesics market showed a degrowth of -0.9 per cent in November.

Among the top performing companies, in the top 10, Mankind had the highest growth of 16.6 per cent, followed by Zydus (including Biochem) at 15.3 per cent, Sun Pharma at 14.9 per cent, Ranbaxy at 11.8 per cent and Lupin at fifth place at 9.8 per cent.

Two companies crossed Rs 300 crore sales in November, the first being the combined entity of Abbott, Abbott Healthcare and Solvay (Rs 317 crore) folllowed by Sun Pharma, at Rs 301 crore.

Without bonus units, Sun Pharma ranked second for the month and MAT for November. Corona Remedies, currently ranked 57, registered a growth of 102 per cent.

AIOCD-AWACS’ PharmaTrac estimates that November recorded extra primary growth in November compared to secondary growth, as sales/demand at retail level (which are audited by PharmaTrac) were lower than in the previous month (possibly due to public holidays like Diwali in November). This anomaly has resulted in more than normal levels of stocks in the market and corresponding lower recorded sales.

Specifically, closing stock days (without in-transit) for November has gone up to 22.3 days as compared to 19.8 days in in the previous month, resulting in 2.5 days of additional inventory in the market.

AIOCD-AWACS’ PharmaTrac estimates that the 2.5 days of additional inventory would have resulted in 8 per cent extra primary growth in November compared to secondary growth, which is reported by PharmaTrac.

Almost all the companies show increase in closing stock over the previous month of October, most notably Macleods (3.8 days), Ranbaxy (2.9 days), and Cipla (2.6 days). Sun Pharma has the least closing stock days, showing an increase of just 1.3 days over October. PharmaTrac estimates that this anomaly should balance out in December.

EP News Bureau

Comments (0)
Add Comment